<DOC>
	<DOCNO>NCT01794208</DOCNO>
	<brief_summary>The aim current study determination recommend standard treatment dose FSH-GEX ( TM ) woman undergo ICSI ( intracytoplasmic sperm injection ) treatment assessed follicle growth .</brief_summary>
	<brief_title>Efficacy Safety FSH-GEX™ Comparison With 150 IU Gonal-f®</brief_title>
	<detailed_description />
	<mesh_term>Infertility</mesh_term>
	<criteria>Female patient ICSI treatment justify serum folliclestimulating hormone concentration Antimullerian hormone concentration Antral follicle count Body mass index body weight Presence ovary Regular spontaneous cycle 21 35 day length Normal uterine cavity assess transvaginal sonography Screening Willing able comply protocol Willing able provide write informed consent Patients two unsuccessful previous assist reproduction technology cycle inclusion study Previous poor responder Patients previous hyperstimulation syndrome cycle cancellation imminent hyperstimulation syndrome Patients history current polycystic ovarian morphology syndrome Patients history current endometriosis III IV Presence ovarian cyst Screening Any contraindication become pregnant History ≥ 3 clinical preclinical miscarriage abnormal cervical smear , Papanicolaou [ PAP ] score ≥ 3 Any history malignant cancer situ breast skin cancer require local excision Any endocrine abnormality require treatment Any clinically significant systematic disease Any known infection human immunodeficiency virus , hepatitis B C History thrombosis risk factor include coagulation abnormality lead increase risk clot Family history genetic risk factor concern pregnancy birth Use concomitant medication , opinion investigator might interfere ICSI preparation procedure Active smoke Any active substance abuse drug , medication alcohol within last five year Patients institution official court order Patients unable unwilling provide inform consent Any participation another clinical trial within last 60 day randomisation Previous FSHGEX™ administration . Known hypersensitivity component investigational non investigational product use study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>37 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>in-vitro fertilization</keyword>
	<keyword>reproductive disorder</keyword>
</DOC>